TOP STORIES

• BUSINESS Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
  February 9, 2016

• REGULATORY Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
  February 8, 2016

• BUSINESS Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
  February 5, 2016

• BUSINESS Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
  February 4, 2016

• BUSINESS Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
  February 3, 2016

• BUSINESS Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
  February 2, 2016

• BUSINESS Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
  February 1, 2016

• BUSINESS Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
  January 29, 2016

• REGULATORY Suspended-but-Shipped Drugs Should Face 20% Price Cut, Chuikyo Member Says amid Kaketsuken Fuss
  January 28, 2016

• TRENDS 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
  January 27, 2016

• TRENDS Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
  January 26, 2016

• REGULATORY Gilead’s 2 Hep C Drugs Likely to Face Some 30% Price Cut under “Huge Seller” Re-Pricing: Jiho Estimate
  January 25, 2016

• ORGANIZATION JPMA Expels Kaketsuken over GMP Violations, Cover-Up
  January 22, 2016

• BUSINESS Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
  January 21, 2016

• REGULATORY “Huge Seller” Re-Pricing to Hit Sovaldi, Harvoni, Avastin, Plavix
  January 20, 2016

• REGULATORY Discussions on Market Price Survey for 2017 Revision Likely to Begin in March, Conclusion Expected in June
  January 19, 2016

• REGULATORY New ICH Trial Guidelines to Embrace “Pooled Populations,” but PMDA Unlikely to Accept Zero Japanese
  January 18, 2016

• REGULATORY Research-Driven Makers Should Find Another Biz Model If They Can’t Innovate: Top Bureaucrat
  January 15, 2016

• BUSINESS Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
  January 14, 2016

• ORGANIZATION JGA Takes Sincerely 50% Pricing Rule for First Generics, There’s Limitation to Data Collection: Chief
  January 13, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 158
• 159
• 160
• 161
• 162
• 163
• 164
• 165
• 166
• …
• Next ›
• 最終 »